Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. Diabetes device companies Dexcom and Abbott are increasing their direct-to-consumer marketing efforts as they compete for a larger share of the growing diabetes market. With insurers now covering continuous glucose monitors for more people, device-makers are adopting strategies commonly used by pharmaceutical companies to promote their products.Agilent Technologies has announced plans to wind down its Resolution Bioscience liquid biopsy unit. The company will discontinue operations at the business it acquired two years ago for $550 million.Tandem Diabetes Care's Chief Commercial Officer, Brian Hansen, is resigning ahead of the company's upcoming rollout of its new insulin pump, called the Mobi Pump.Google Cloud's Amy Waldron discussed the tech giant's ambitions in healthcare and the potential risks associated with generative artificial intelligence (AI) in the industry. Generative AI has the ability to create new content, such as images and text, but there are concerns about the ethical implications and potential biases that may arise.The Washington Post reports on the changing landscape of healthcare delivery, with state laws allowing non-doctors to treat patients. AP News highlights the mental health challenges faced by survivors of the Maui wildfire. The CDC is working to overhaul its lab operations following issues with COVID-19 testing. Medical Device and Diagnostic Industry explores the use of plastic in medical devices and its environmental impact.Gilead Sciences has faced another setback with its cancer drug, as the FDA partially halted leukemia studies of the drug. This drug was the center of Gilead's $5 billion acquisition of biotech company Forty Seven in 2020.Regeneron Pharmaceuticals rebounded by winning FDA approval for a longer-lasting vision loss drug called high-dose Eylea. The drug was cleared less than two months after it was initially rejected by the FDA. Additionally, the agency also approved a separate Regeneron drug for an ultra-rare disease.The FDA expanded the use of a neurocrine drug called Ingrezza to include Huntington's disease patients with a movement disorder known as chorea. This approval is expected to intensify the commercial battle between neurocrine and Teva Pharmaceuticals.Genesis, a California startup focused on AI drug discovery research, raised $200 million in a series B funding round. The total funding for Genesis now exceeds $280 million

Id. d’épisode : 1000625220892

GUID : Buzzsprout-13445387

Date de publication : 22/8/2023 à 07:00:00